Press release released: September 29, 2019 (Sun)
>> See press release here
Presentation webcast & call: September 30, 2019 (Mon)
2pm CEST (1pm BST/8am EDT/8pm HKT)
>> Click here for the webcast replay
MA14.05 - A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA)
Venue: IASLC 2019 World Conference on Lung Cancer in Barcelona, Spain
Session:MA14 - The Adequate MTarget
地址： Westin St. Francis Hotel, San Francisco, CA
日期： 2019年1月9日（星期三）
时间： 9:30am PST (12:30pm EST/5:30pm BST)
录音： 请下载附带的演示文稿
[audio mp3="http://www.chi-med.com/wp-co
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
The FRESCO Randomized Clinical Trial
Jin Li; Shukui Qin; Rui-Hua Xu; Lin Shen; Jianming Xu; Yuxian Bai; Lei Yang; Yanhong Deng;
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer treated with fruquintinib in FRESCO
Presenter:
Yu-Xian Bai
Other Authors:
Hongyan Li, Ning Wang, Xiaojun Guo, Wei Wang, Songhua F
4541 / 26 - MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor
Presenter/Authors
M. M. Frigault1, S. Signoretti2, A. Markovets
Pharmacokinetics of Fruquintinib in Humans
Venue: American Society for Clinical Pharmacology & Therapeutics Annual Meeting in Orlando, Florida, USA
Abstract #: PII-116
Authors: Ke Li, Chen Yu, Yanmei Liu, Xiangkun Li, Sumei Xia, Jian Wa
Announcement released: 7am BST (3pm HKT/3am EDT)
» See announcement here
Presentation webcast & call: 9am BST (5pm HKT/5am EDT)
» Click here for a video of the webcast
US conference call: 9am EDT (1pm BST/9pm HKT)
Shun Lu, Jianhua Chang, Xiaoqing Liu, Jianhua Shi, You Lu, Wei Li, Jin-ji Yang, Jianying Zhou, Jie Wang, Tongtong An, Lei Yang, Zhe Liu, Xiangdong Zhou, Mo Chen, Ye Hua and Weiguo Su
Abstract
Purpose
Patients with advanced non‒small-cell lung
Venue: The 13th International Conference of the Asian Clinical Oncology Society in Chiang Mai, Thailand
Abstract #: ABS093
Authors: Jin Li, Shukui Qin, Yuxian Bai, Yanhong Deng, Lei Yang, Zhendong Chen, Haijun Zhong, Rui-hua Xu, Hongming Pan,
A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Savolitinib in Patients with Metastatic Renal Cell Carcinoma
S Vari1, B Szabados1, A GomezdeLiano1, K Mousa2, L Rammazzo2, A Prendergast2, T Powles1
1 Barts Health NHS Trust, Barts Can
OA 09.06 – A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC
Jin-Ji Yang, Jian Fang, Y. Shu, J. Chang, G. Chen, J. He, W. Li, X. Liu, N. Yang, Caicun Zhou, J. Huang, L. Yang, A.A. Han
OA 09.03 – TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI
Myung-Ju Ahn, Ji-Youn Han, Lecia V Sequist, Byoung Chul Cho, J.S. Lee, Sang-We Kim, W. Su, C. T
JCSE 01.12 – A Phase II study of fruquintinib in combination with gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations (NCT02976116)
Shun Lu, Jianying Zhou, Xiaomin Niu, Mo Chen, Hongyan Yin, Ye Hua, Weiguo Su
Venue: IA
Phase Ib Trial of the Safety and Antitumor Activity of Savolitinib in Advanced Gastric Cancer Patients with Aberrant c-MET
Jifeng Feng, Baorui Liu, Tianshu Liu, Nong Xu, Jianming Xu, Yunpeng Liu, Yuxian Bai, Jin Li, Wei Li, Chunmei Bai, Tao Zhang,
Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial
Lin Shen, Li Zhang, Hongyun Zhao, Wenfeng Fang, Jifang Gong
Venue: Chinese Society of Clinical Oncology Annual Meeting
Session: Esophageal Cancer
Presenter: Jif
In-depth Analysis of the FRESCO Study: a Randomized, Double-blind, Phase III Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients with 3+ Line Advanced Colorectal Cancer
Shukui QIN*, Jin LI*, Yuxian BAI, Yanhong DENG, Lei YANG, Zhen
The Royal Society of Medicine, London, UK
Please visit rsm.ac.uk for more information.
A video recording of the 20-minute presentation is available.
RSM video link
Note: there is a 25-second audio error at 2:55.
Announcement released: 7am BST (2am EDT, 2pm HKT)
» See announcement here
Presentation webcast & call: 9am BST (4pm HKT)
» click here for a video of the webcast
US conference call: 9am EDT (2pm BST)
» To parti
Toni K. Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, Eric Jonasch, Daniel Y.C. Heng, Thomas Powles, Melanie M. Frigault, Edwin A. Clark, Amir A. Handzel, Humphrey Gardner, Shethah Morgan, Laurence Albiges, and Sumanta Kumar Pal
Abstract
Pur
A randomized, double-blind, placebo-controlled, multi-centered phase III trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO)
Venue: American Society of Clinical Oncol
A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC)
Venue: American Society of Clinical Oncology Annual Meeti
Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models
Authors: Yongxin Ren, Qiaoling Sun, Jingwen Long, Shiming Fan, Renxiang Tang,
Introduction
The Future of Targeted Cancer Therapy In Lung Cancer
Post-POC Portfolio
Pre-POC Portfolio
Research Strategy
Transforming into a Fully Integrated Global Biopharma
Wed. Mar 29, 9:30am - South Place Hotel, London, UK
» Cli
Announcement released: 7am GMT
» See announcement here
Webcast presentation & conf call: 9am GMT (5pm HKT)
» click here for a video of the webcast (available for six months)
» To participate by phone, please us
An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967)
Authors: J.M. Xu, J. Li, C.M. Bai, N. Xu, Z.W. Zhou, Z.P. Li, C.C. Zhou, W. Wang, J. Li, C. Qi, Y. Hua, W.G. Su
Summary: The current Phase
A Phase I/II Trial of Fruquintinib in Combination with Paclitaxel for Second-line Treatment in Patients with Advanced Gastric Cancer
Ruihua Xu, Dongsheng Zhang, Lin Shen, Jin Li, Jing Huang, Yang Zhang, Jifang Gong, Weijian Guo, Songhua Fan, Ke Li,
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
Authors: Rui-Hua Xu, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin She
A Randomized, Multi-Center, Double-Blind Phase II Study of Fruquintinib in Patients with Advanced Non-Small Cell Lung Cancer (NCT02590965)
Shun Lu1, Jianhua Chang2, XiaoQing Liu3, Jianhua Shi4, You Lu5, Wei Li6, Jinji Yang7, Jianying Zhou8, Jie Wa
A Phase Ib study of Epitinib to evaluate efficacy and safety in EGFR mutation positive (EGFRm+) NSCLC patients with brain metastasis
Qing Zhou1, Bin Gan1, Qunying Hong2, Mengzhao Wang3, XiaoQing Liu4, Liwei Yuan5, Ye Hua5, Hongcan Ren5, Weiguo Su5,
A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of HMPL-523 in Australian Male Healthy Subjects
Background: S